ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology
2016
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
10
Citations
NaN
KQI